Rallybio's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Rallybio's ROI in the third quarter of 2026?
Rallybio Corporation achieved a return on average invested assets (ROI) of 36.04 % in its third quarter of 2026, this is above RLYB's average return on investment of -44.2%.
Rallybio Corporation invested over the 12 months ending in its third quarter of 2026 $74 million

ROI decreased relative to the period ending Jun 30 2026, due to the decline in net income.

Within the Healthcare sector 22 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the second quarter of 2026 from 2813 to 3206.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Investment Change TTM	32.22 %	14.67 %	-18.56 %	-26.8 %	-35.09 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	94	95	50	58	63
Return On Investment (TTM)	36.04 %	68.28 %	-14.38 %	-16.23 %	-25.19 %
RLYB's Overall Ranking	# 3206	# 2813	# 2963	# 2935	#
Seq. Investment Change TTM	11.5 %	22.71 %	-1.69 %	-1.7 %	-3.3 %
Seq. Net Income Change TTM	-41.14 %	-	-	-	-
Net Income (TTM) in Millions	27	46	-8	-9	-14

RLYB Company Profile >> Back to RLYB Roi Comparisons >> See Annual RLYB Return On Investment

Return On Investment RLYB's Ranking
Within:	No.
Industry	# 12
Sector	# 23
Overall	# 3206

Return On Investment Statistics
High	Average	Low
68.28 %	-44.2 %	-77.27 %
(Jun 30 2026)		(Sep 30 2024)

News about Rallybio Corporation Return on Investment ROI

Rallybio Corporation Heralds Progress in Thrombosis Research Amid Financial Challenges

August 29, 2024

In the hallowed chambers of medical advancement, the Rallybio Corporation, a beacon within the ever-evolving landscape of biotechnology, unveiled a significant milestone befitting the relentless pursuit of alleviating human suffering from rare ailments. With headquarters nestled in the industrious borough of New Haven, Connecticut, this clinical-stage enterprise, known to the discerning circles of investors and scholars alike under the ticker symbol RLYB on the Nasdaq, recently announced the publication of its findings from a Phase 1 proof-of-concept study involving RLYB212 a novel monoclonal anti-HPA-1a antibody. This innovative therapeutic endeavor seeks to stave off maternal alloimmunization, a perilous condition that may lead to fetal and neonatal alloimmune thrombocytopenia (FNAIT), thus safeguarding the fragile lives of the next generation.The study s findings, now gracing the esteemed journal Thrombosis and Haemostasis , herald the dawn of a potential paradigm shift in the preventative approach towards FNAIT, an affliction that has long posed significant health risks to neonates. The enlightened research into RLYB212 exemplifies the application of scientific ingenuity intended to translate into the tangible betterment of human health a noble venture in a time beset by health inequities.

Financial Statements
Rallybio's III. Quarter Investments	$ 94 Millions	RLYB's Balance sheet
Rallybio's III. Quarter Income	$ -3 Millions	Quarterly RLYB's Income Statement
RLYB's Income by Division		See RLYB's Income by Division

RLYB Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	58	62	106	170	176
Y / Y Investment Growth	-6.19 %	-41.83 %	-37.32 %	-3.38 %	-
Net Income in Millions	-9	-58	-75	-67	-26
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-15.47 %	-93.39 %	-70.11 %	-39.28 %	-15.06 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
RLYB's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for RLYB's Competitors
Subscribers only: Roi for Rallybio's Suppliers
Subscribers only: Return On Investment for RLYB's Customers

Other Ratios
RLYB's Roa	RLYB's Inventory Turnover Ratio	RLYB's Growth Rates	RLYB's Dividend Statistics
	RLYB's Profitability Ratios	RLYB's Asset Turnover Ratio	RLYB's Dividend Growth
RLYB's Roe	RLYB's Valuation Ratios	RLYB's Financial Strength Ratios	RLYB's Dividend Payout Ratio

Companies with similar Return On Investment at Sep 30 2026, within Healthcare Sector	ROI
Exelixis Inc	75.01 %
Ironwood Pharmaceuticals inc	68.68 %
Rigel Pharmaceuticals Inc	68.50 %
Alnylam Pharmaceuticals Inc	63.14 %
Idexx Laboratories Inc	52.51 %
Aurinia Pharmaceuticals Inc	45.04 %
Nurix Therapeutics Inc	44.12 %
Medpace Holdings Inc	41.14 %
Rallybio Corporation	36.04 %
Eli Lilly And Company	32.00 %
Caredx Inc	30.65 %
Zevra Therapeutics Inc	29.88 %
Acadia Pharmaceuticals Inc	26.89 %
Standard Biotools Inc	23.91 %
Iradimed Corporation	22.98 %
Corcept Therapeutics Inc	22.08 %
Resmed Inc	21.10 %
Alector Inc	20.83 %
Chemed Corporation	20.46 %
Halozyme Therapeutics Inc	19.64 %
Pro dex Inc	19.11 %
Dexcom Inc	18.92 %
Illumina Inc	18.74 %
Denali Therapeutics Inc	17.88 %
West Pharmaceutical Services Inc	17.65 %
Healthcare Services Group Inc	17.18 %
Neurocrine Biosciences Inc	16.94 %
Krystal Biotech Inc	16.91 %
Vertex Pharmaceuticals Inc	16.63 %
Intuitive Surgical Inc	16.30 %

Date modified: 2026-10-28T09:27:47+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.